5403-Walsh, James
Faculty

James P. Walsh, MD, PhD

Associate Professor of Medicine

Address
Veterans Administration Medical Center, Room 111 E
1481 W. 10th St.

Indianapolis, IN 46202-2884

Bio

Dr. Walsh earned his MD and PhD degrees at Duke University. He did his Internal Medicine residency at Washington University in St. Louis and his Endocrinology fellowship at the University of Washington in Seattle.  He joined the Indiana University faculty in 1995 and is currently Endocrinology Section Chief at the Roudebush VA Medical Center. He has conducted basic and clinical studies of lipid metabolism for many years. He is currently the site principal investigator for two cardiovascular outcome trials, PROMINENT and TRAVERSE. His clinical interests include lipid disorders, cardiovascular outcomes in diabetes, thyroid diseases and hypogonadism in older men

Key Publications

Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade. Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF, VA NEPHRON-D Study. Clin J Am Soc Nephrol 2016, 11:1944-53.

My approach to testosterone replacement in older men. Walsh JP. Trends Cardiovasc Med 2016, 26:295-6.

BP and renal outcomes in diabetic kidney disease: The Veterans Affairs nephropathy in diabetes trial. Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF; VA NEPHRON-D Study Group. Clin J Am Soc Nephrol 2015, 10:2159-69.

PCSK9 inhibitors for LDL lowering. Walsh JP. Trends Cardiovasc Med 2015, 25:575-7.

Testosterone therapy and cardiovascular risk. Walsh JP, and Kitchens AC. Trends Cardiovasc Med 2015, 25:250-7.

Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy. Zimering MB, Zhang JH, Guarino PD, Emanuele N, McCullough PA, Fried LF; Investigators for the VA NEPHRON-D. Front Endocrinol (Lausanne) 2014, 5:128.

Combined angiotensin inhibition for the treatment of diabetic nephropathy. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators.  N Engl J Med 2013, 369(20):1892-903.

Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King S 3rd, Colling C, Moritz T, Stroupe K, Reda D and the VA CARDS Investigators. J Am Coll Cardiol 2013 Feb 26;61(8):808-16.

Lanthanum carbonate interference with lumbar spine DXA. Walsh JP, and Lteif AA. J Clin Densitom 2011, 14:499-501.

Type B insulin resistance developing during interferon-alpha therapy. Daniel AL, Houlihan JL, Blum JS, and Walsh JP. Endocr Pract 2009, 15:153-7.

Lipid modulation of the activity of diacylglycerol kinase alpha- and zeta-isoforms: activation by phosphatidylethanolamine and cholesterol

Fanani ML, Topham MK, Walsh JP, and Epand RM. Biochemistry 2004, 43:14767-77.

 

L-carnitine may attenuate free fatty acid-induced endothelial dysfunction.

Shankar SS, Mirzamohammadi B, Walsh JP, and Steinberg HO.  

Ann NY Acad Sci 2004, 1033:189-97. 

 

Site-directed mutagenesis of the active site of diacylglycerol kinase alpha: calcium and phosphatidylserine stimulate enzyme activity via distinct mechanisms. Abe T, Lu X, Jiang Y, Boccone RC, Qian S, Vattem KR, Wek R, and Walsh JP. Biochem J 2003, 375: 673-80.

 

A method for quantitative extraction of sphingosine 1-phosphate into organic solvent. Kralik S, Du X, Patel C, and Walsh JP. Anal Biochem 2001, 294:190-3.

 

Fatty acids Inhibit growth factor-induced diacylglycerol kinase alpha activation in vascular smooth muscle cells. Du X, Jiang Y Qian W, Lu X, and Walsh JP. Biochem J 2001, 357:275-82.

 

A domain with homology to neuronal calcium sensors is required for calcium-dependent activation of diacylglycerol kinase alpha. Jiang Y, Qian W, Hawes JW, and Walsh JP. J Biol Chem 2000, 275:34092-9.

 

Fatty acids amplify platelet-derived growth factor-induced protein kinase C activation in vascular smooth muscle cells independently of their effect on de novo diacylglycerol synthesis. Lu X, Yang X-Y, Howard RL, and Walsh JP.  Diabetologia 2000, 43:1136-44.

Titles & Appointments

  • Associate Professor of Medicine
  • Associate Professor of Biochemistry & Molecular Biology
  • Education
    1995 FEL University of Washington (Seattle)
    1990 RES Washington University (St. Louis)
    1987 MD Duke University
    1986 PhD Duke University
  • Research

    Dr. Walsh conducts cardiovascular clinical trials. Randomized, double-blind trials evaluating cardiovascular outcomes in subjects with type 2 diabetes treated with an investigational fibrate (PROMINENT) and in older men treated with testosterone (TRAVERSE) are underway. A trial of statin therapy for primary prevention in adults over 75 (PREVENTABLE) will begin enrolling in the second half of 2020.

  • Professional Organizations
    American Association of Clinical Endocrinology
    American Diabetes Association
    American Society for biochemistry and Molecular biolog
    Endocrine Society
  • Board Certifications
    American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine - Internal Medicine
  • Clinical Interests

    Clinical lipidology

    Cardiovascular outcomes in diabetes

    Thyroid ultrasound and FNA

    Hypogonadism in older men

Research Labs

Faculty research at IU School of Medicine is transforming health. Details about the medical research being conducted in faculty labs throughout IU School of Medicine are available in the Research section of this site.

Faculty Labs